SANCC: Clinical Trial Early Intervention

Inclusion Criteria: * Male or female individuals older than two years with a diagnosis of asymptomatic SANCC confirmed by MRI. * SANCC limited to the basal cisterns, the interhemispheric brain space, brain fissures or spine. * Baseline laboratory results within acceptable ranges (specifically defined in the study protocol) * Willingness to accomplish the two-week minimum hospitalization required. Exclusion Criteria: * Individuals who only have subarachnoid lesions in the convexity of the brain hemispheres will not be included because these lesions commonly respond well to therapy and behave as intraparenchymal lesions * Co-occurrence of a) more than 20 intraparenchymal lesions in addition to their subarachnoid disease, or b) intraparenchymal lesions greater than 3.0 cm of diameter * Individuals for whom a surgical intervention to treat their subarachnoid disease is considered clearly superior to a medical intervention * Previously diagnosis or treatment for cysticercosis. * Active pulmonary tuberculosis evidenced by chest X-ray and positive sputum smears, or symptoms compatible with tuberculosis (fever+sweats or fever+cough) not otherwise explained * Individuals with positive markers for active hepatitis * Other systemic disease that may affect therapy or short-term prognosis, including but not limited to chronic renal failure, hepatic insufficiency, cardiac failure, or steroid-dependent immune diseases * Pregnancy. If a participant becomes pregnant during the study, she will continue in the study but will have radiological exams delayed until after delivery * History of hypersensitivity to ABZ * Chronic alcohol or drug abuse as defined in the study protocol * Unwilling or unable to provide MRI exams (e.g. patients with ferromagnetic implants) * Inability or unwillingness of subject or legal representative to give written informed consent.